Emcure Pharmaceuticals has allotted 17,000 equity shares to employees under its ESOS 2013 scheme following committee approval on March 03, 2026. The allotment increased the company's paid-up share capital from Rs. 1,89,57,25,470 to Rs. 1,89,58,95,470, with total equity shares rising to 18,95,89,547. The newly issued shares carry equal rights with existing equity shares and comply with SEBI listing regulations.
Emcure Pharmaceuticals has completed the allotment of 17,000 equity shares to eligible employees under its Employee Stock Option Scheme 2013 (Emcure ESOS 2013). The allotment was approved through a Resolution by Circulation by the company's Nomination and Remuneration Committee on March 03, 2026.
ESOP Allotment Details
The allotment follows the exercise of 17,000 vested stock options by eligible employees under the Emcure ESOS 2013 scheme. Each equity share carries a face value of Rs. 10 and the newly issued shares will enjoy equal rights with existing equity shares of the company.
Parameter: Details Shares Allotted: 17,000 equity shares Face Value: Rs. 10 per share Scheme: Emcure ESOS 2013 Approval Date: March 03, 2026 Approving Authority: Nomination and Remuneration Committee
Impact on Share Capital
The allotment has resulted in an increase in the company's issued and paid-up share capital. The capital structure has been revised following the incorporation of the newly allotted shares.
Capital Component: Before Allotment After Allotment Number of Shares: 18,95,72,547 18,95,89,547 Face Value per Share: Rs. 10 Rs. 10 Total Paid-up Capital: Rs. 1,89,57,25,470 Rs. 1,89,58,95,470
Regulatory Compliance
The allotment was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both the National Stock Exchange of India Limited and BSE Limited about this corporate action as required under the regulatory framework.
The newly allotted equity shares will rank pari passu in all aspects with the existing equity shares of Emcure Pharmaceuticals, ensuring equal treatment for all shareholders. This ESOP exercise demonstrates the company's commitment to employee participation in its growth and value creation.
Emcure Pharmaceuticals has officially announced a strategic distribution agreement with global pharmaceutical giant Roche for nephrology and transplant products in the Indian market. The partnership, formalized through a press release dated March 2, 2026, will commence on April 1, 2026, marking a significant expansion in Emcure's therapeutic portfolio.
Partnership Details
The distribution agreement encompasses three specialized pharmaceutical brands essential in nephrology and transplant care:
Product: Therapeutic Application CellCept® Immunosuppressant for organ transplants (available since 1995) Mircera® Long-acting ESA for anemia in chronic kidney disease NeoRecormon® Proven therapy for anemia management
Leadership Perspectives
Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals, commented on the partnership: "This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach."
Rajji Mehdwan, Managing Director & CEO of Roche India & Neighbouring Markets, stated: "We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure's strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients."
Strategic Market Position
Emcure Pharmaceuticals is recognized as a market leader in anemia management and maintains a strong presence across nephrology and chronic kidney disease segments. The company is ranked as the 13th largest pharmaceutical company in India in terms of domestic sales for MAT October 2025, with operations spanning over 70 countries globally.
Product Portfolio Enhancement
The collaboration focuses on expanding patient access to critical therapies in chronic kidney disease, anemia management, and transplant care across India. CellCept® represents Roche's original innovation supporting organ transplants worldwide, while Mircera® offers long-acting treatment with dosing flexibility of once every 2-4 weeks for chronic kidney disease patients.
Implementation and Market Impact
The partnership leverages Emcure's established distribution network and clinical engagement capabilities to improve patient access to proven therapies. The collaboration aims to support physicians in delivering optimal care while enhancing anemia management and long-term outcomes for patients with chronic kidney disease and transplant requirements.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
